Surgical Innovations Group (LSE:SUN) ROCE % : -4.87% (As of Dec. 2023)

View and export this data going back to 1988. Start your Free Trial

What is Surgical Innovations Group ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Surgical Innovations Group's annualized ROCE % for the quarter that ended in Dec. 2023 was -4.87%.

Surgical Innovations Group ROCE % Historical Data

The historical data trend for Surgical Innovations Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surgical Innovations Group ROCE % Chart

Surgical Innovations Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-15.96

-22.61

-3.55

0.34

-4.89

Surgical Innovations Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															-5.00	-0.99	1.60	-4.94	-4.87

Surgical Innovations Group ROCE % Calculation

Surgical Innovations Group's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-0.596	/	( ( (15.595 - 2.92)	+	(14.32 - 2.62) )	/ 2 )
	=	-0.596	/	( (12.675	+	11.7)	/ 2 )
	=	-0.596	/	12.1875
	=	-4.89 %

Surgical Innovations Group's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-0.58	/	( ( (15.33 - 3.205)	+	(14.32 - 2.62) )	/ 2 )
	=	-0.58	/	( ( 12.125	+	11.7 )	/ 2 )
	=	-0.58	/	11.9125
	=	-4.87 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Surgical Innovations Group (LSE:SUN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Surgical Innovations Group ROCE % Related Terms

Thank you for viewing the detailed overview of Surgical Innovations Group's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Surgical Innovations Group (LSE:SUN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Surgical Innovations Group PLC (LSE:SUN) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Clayton Wood House, 6 Clayton Wood Bank, Leeds, GBR, LS16 6QZ

Website

https://www.sigroupplc.com

Surgical Innovations Group PLC is involved in the design, development, manufacture, and sale of devices for use in minimally invasive surgery and precision engineering markets. The group sells branded products through independent healthcare distributors across the world and own-label products through original equipment manufacturer relationships. The SI Brand segment includes research, development, manufacture, and distribution of SI branded minimally invasive devices. The OEM segment includes the research, development, manufacture, and distribution of minimally invasive devices for third-party medical device companies through either own label or co-branding. The distribution segment includes the distribution of specialist medical products.